Petauri

Overview

Petauri is the current operating name for the Oak Hill Capital-backed pharma services platform formed in February 2023 and built through the acquisitions of The Kinetix Group (TKG, now Petauri Kinect), the Brightly Network medical-communications agencies (Bluprint Oncology, Cogency, Momentum, Propel, Verascity Science), Formulary Insights, Artia Solutions, FORCE Communications, Mtech Access, and Delta Hat. Buyers searching Petauri Health or any of those acquired brand names should evaluate Petauri as the current entity.

Petauri is a rolled-up market-access and communications platform; it is not a single-practice strategy boutique or a hub-services operator. The buyer thesis is that pricing, evidence, payer marketing, medical communications, and Medicaid strategy are coordinated under one platform; the buyer risk is that the operating unit doing the actual work may not have changed since the legacy brand’s pre-acquisition state.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Petauri is evaluated as an integrated market-access, HEOR, medical-communications, and access-strategy platform assembled from Kinetix, Formulary Insights, Artia, FORCE Communications, Mtech Access, and related legacy brands.

Capability	Buyer should compare	Petauri readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core. Petauri Advisors (anchored by Formulary Insights staff) and the ACE team of ex-payer/health-system operators carry the access-strategy lane.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Core. Pricing and contracting sit inside Petauri Advisors / Petauri Evidence; confirm which unit owns the deliverable.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Core. Petauri Evidence (anchored by Mtech Access and Delta Hat) is the HEOR/value lane.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Core. ACE team provides operator-level payer input; FIRST is the rapid-insight tool.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Core. Artia Solutions (acquired Jul 2025) brings state Medicaid and supplemental-rebate expertise that few peers carry in-house.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Core. Petauri Advance (Brightly-anchored medical/scientific communications) plus Petauri Kinect (multistakeholder collaboration) handle launch execution and HCP engagement.

Buyer Fit

• Launch-team fit: Manufacturers that want pricing, evidence, payer marketing, medical communications, and Medicaid strategy under one platform rather than five separate vendor relationships.
• Best-fit buyers: Mid-sized to large pharma with multi-workstream launches; emerging biotechs needing access plus med comms plus Medicaid in one engagement.
• Less ideal fit: Buyers seeking a single senior strategy boutique with one named operator; buyers who prefer best-of-breed specialist boutiques over a bundled platform.
• Commercial fit: Custom/RFP; expect a Petauri Advisors / Evidence / Advance / Kinect / MAx unit assignment per workstream.
• Program diligence: Which Petauri operating unit is doing the work, which legacy team within that unit, and how the platform governs cross-unit deliverables.

Differentiators

• ACE team of ex-payer/health-system operators: Real payer/health-system decision-makers on staff, not just consultants briefed by them.
• Artia Solutions Medicaid expertise: State Medicaid programs and supplemental rebate negotiations as a documented in-house capability.
• Brightly Network medical-communications agencies: Bluprint Oncology, Cogency, Momentum, Propel, and Verascity Science give the platform genuine scientific-communications scale.
• FIRST proprietary frontline-payer-insight tool: Useful diligence item when access strategy must be sharpened quickly before launch.
• Oak Hill buy-and-build cadence: 7 add-ons in ~30 months since platform formation; the integration risk is the buyer’s diligence item.

RFP Questions

• Which Petauri operating unit (Advisors, Evidence, Advance, Kinect, MAx) will own each workstream, and who is the named senior operator?
• Which legacy team within the assigned unit is the actual delivery team (Formulary Insights, Mtech, Brightly agency, Artia, TKG, etc.)?
• How are cross-unit deliverables (access + HEOR + med comms + Medicaid) reconciled into one launch plan?
• What is the FIRST tool’s data source, refresh cadence, and panel composition, and which outputs are deliverable vs. internal-only?
• Which Medicaid analogs from Artia can the team cite for our therapy area and payer mix?
• How will payer ad boards, mock P&T panels, and primary research be staffed and governed?
• What change-order and pass-through-cost patterns apply across the bundled Petauri scope?

Recent Activity

• 2025-11 - Lisa Hefner appointed Group President of Petauri Advance, overseeing scientific-communications agencies (Bluprint Oncology, Verascity Science).
• 2025-07 - Acquired Artia Solutions (Tallahassee, FL), deepening Medicaid and supplemental-rebate expertise.
• 2024-11 - Acquired Formulary Insights (Indianapolis, IN), folded into Petauri Advisors.
• 2024-07 - Acquired the Brightly Network (Bluprint Oncology, Cogency, Momentum, Propel, Verascity Science) for $46.5M, pushing platform headcount past 360.
• 2023-06 - Acquired The Kinetix Group / TKG; rebranded as Petauri Kinect.
• 2023-07 - Mridul Malhotra joined as Chief Strategy Officer and Global Head of Evidence, Value, and Access; drives platform M&A strategy.
• 2023-02 - Oak Hill Capital formed Petauri Health (later Petauri) with >$250M of equity commitment from Oak Hill Capital Partners VI.